Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin, vancomycin and taurolidine for prevention of dialysis catheter infection
IRCT20190529043748N1Phase 2Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- May 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of heparin, vancomycin and taurolidine in catheter infection and end-stage kidney disease (ESKD), sponsored by Babol University of Medical Sciences. Started May 2019; status: completed.
02
Drugs
heparinvancomycintaurolidine
03
Conditions
catheter infectionend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20190529043748N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190529043748N1.